Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2- Breast Cancer at a Single Cancer Center.


Journal

The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837

Informations de publication

Date de publication:
05 08 2022
Historique:
received: 05 10 2021
accepted: 18 03 2022
pubmed: 7 6 2022
medline: 10 8 2022
entrez: 6 6 2022
Statut: ppublish

Résumé

A study was initiated at Roswell Park Comprehensive Cancer Center to capture the real-world experience related to the use of CDK4/6 inhibitors (Ciclibs) for the treatment of metastatic hormone receptor-positive and HER2-negative breast cancer (HR+/HER2-). A total of 222 patients were evaluated who received CDK4/6 inhibitors in the period from 2015 to 2021. Detailed clinical and demographic information was obtained on each patient and used to define clinical and demographic features associated with progression-free survival on CDK4/6 inhibitor-based therapies. In this real-world analysis, the majority of patients received palbociclib as the CDK4/6 inhibitor with letrozole or fulvestrant as the predominant endocrine therapies. The median progression-free survival (PFS) in the letrozole (27.6 months) and fulvestrant (17.2 months) groups were comparable to that observed in clinical trials. As expected, age at start of the treatment and menopausal status influenced endocrine therapy utilization but were not associated with PFS. Patients with recurrent disease had shorter PFS (P = .0024) than those presenting with de novo metastasis. The presence of visceral metastasis trended toward shorter PFS (P = .051). Similarly, prior endocrine therapy (P = .003) or chemotherapy (P = .036) was associated with shorter PFS. Body mass index was not associated with PFS or with dose interruption and/or modification. While the number of minorities in this analysis is limited (n = 26), these patients as a group had statistically shorter PFS on treatment (P = .002). The real-world progression-free survival with CDK4/6 inhibitors mimics that observed in the clinical trial. A number of clinical and demographic features were associated with PFS on CDK4/6 inhibitor-based therapy. Further studies are ongoing to validate these findings incorporating additional cancer centers.

Sections du résumé

BACKGROUND
A study was initiated at Roswell Park Comprehensive Cancer Center to capture the real-world experience related to the use of CDK4/6 inhibitors (Ciclibs) for the treatment of metastatic hormone receptor-positive and HER2-negative breast cancer (HR+/HER2-).
PATIENTS AND METHODS
A total of 222 patients were evaluated who received CDK4/6 inhibitors in the period from 2015 to 2021. Detailed clinical and demographic information was obtained on each patient and used to define clinical and demographic features associated with progression-free survival on CDK4/6 inhibitor-based therapies.
RESULTS
In this real-world analysis, the majority of patients received palbociclib as the CDK4/6 inhibitor with letrozole or fulvestrant as the predominant endocrine therapies. The median progression-free survival (PFS) in the letrozole (27.6 months) and fulvestrant (17.2 months) groups were comparable to that observed in clinical trials. As expected, age at start of the treatment and menopausal status influenced endocrine therapy utilization but were not associated with PFS. Patients with recurrent disease had shorter PFS (P = .0024) than those presenting with de novo metastasis. The presence of visceral metastasis trended toward shorter PFS (P = .051). Similarly, prior endocrine therapy (P = .003) or chemotherapy (P = .036) was associated with shorter PFS. Body mass index was not associated with PFS or with dose interruption and/or modification. While the number of minorities in this analysis is limited (n = 26), these patients as a group had statistically shorter PFS on treatment (P = .002).
CONCLUSIONS
The real-world progression-free survival with CDK4/6 inhibitors mimics that observed in the clinical trial. A number of clinical and demographic features were associated with PFS on CDK4/6 inhibitor-based therapy. Further studies are ongoing to validate these findings incorporating additional cancer centers.

Identifiants

pubmed: 35666660
pii: 6603354
doi: 10.1093/oncolo/oyac089
pmc: PMC9355808
doi:

Substances chimiques

Receptors, Estrogen 0
Receptors, Progesterone 0
Fulvestrant 22X328QOC4
Letrozole 7LKK855W8I
Receptor, ErbB-2 EC 2.7.10.1
CDK4 protein, human EC 2.7.11.22
Cyclin-Dependent Kinase 4 EC 2.7.11.22

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

646-654

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press.

Références

Nat Rev Dis Primers. 2019 Sep 23;5(1):66
pubmed: 31548545
Nature. 2019 Mar;567(7748):399-404
pubmed: 30867590
Cancer Treat Res. 1988;39:51-65
pubmed: 2908608
J Natl Cancer Inst. 2021 Apr 6;113(4):462-470
pubmed: 32750143
Lancet Oncol. 2020 Feb;21(2):250-260
pubmed: 31859246
Nat Rev Drug Discov. 2015 Feb;14(2):130-46
pubmed: 25633797
Lancet Oncol. 2015 Jan;16(1):25-35
pubmed: 25524798
Lancet Oncol. 2019 Oct;20(10):1360-1369
pubmed: 31494037
J Clin Oncol. 2019 May 10;37(14):1169-1178
pubmed: 30807234
Trends Cancer. 2017 Jan;3(1):39-55
pubmed: 28303264
Am Soc Clin Oncol Educ Book. 2020 May;40:115-126
pubmed: 32421454
Rev Endocr Metab Disord. 2007 Sep;8(3):215-28
pubmed: 17486453
Nat Rev Clin Oncol. 2016 Jul;13(7):417-30
pubmed: 27030077
N Engl J Med. 2012 Feb 9;366(6):520-9
pubmed: 22149876
J Clin Oncol. 2020 Dec 1;38(34):3987-3998
pubmed: 32954927
J Clin Oncol. 2017 Sep 1;35(25):2875-2884
pubmed: 28580882
Endocr Relat Cancer. 2011 Apr 28;18(3):333-45
pubmed: 21367843
Clin Cancer Res. 2015 Nov 15;21(22):5121-5130
pubmed: 25991817
J Clin Oncol. 2017 Nov 10;35(32):3638-3646
pubmed: 28968163
Breast Cancer Res. 2009;11(5):R77
pubmed: 19874578
Cancer Discov. 2020 Aug;10(8):1174-1193
pubmed: 32404308
Clin Cancer Res. 2008 Dec 15;14(24):8019-26
pubmed: 19088018
Cancer. 1977 Jun;39(6 Suppl):2934-47
pubmed: 326386
JAMA. 2019 Jan 22;321(3):288-300
pubmed: 30667505
Lancet Oncol. 2016 Apr;17(4):425-439
pubmed: 26947331
Nat Rev Clin Oncol. 2019 Jul;16(7):406-408
pubmed: 31092902
J Clin Oncol. 2019 Jan 10;37(2):105-114
pubmed: 30475668
Breast Cancer Res Treat. 2018 Feb;168(1):127-134
pubmed: 29164421
Breast. 2009 Oct;18 Suppl 3:S141-5
pubmed: 19914534
J Clin Oncol. 2018 Aug 20;36(24):2465-2472
pubmed: 29860922
Cancer Res. 2021 Mar 1;81(5):1347-1360
pubmed: 33323381

Auteurs

Erik S Knudsen (ES)

Department of Molecular and Cellular Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

Emily Schultz (E)

Center for Personalized Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

Deanna Hamilton (D)

Center for Personalized Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

Kris Attwood (K)

Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

Stephen Edge (S)

Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

Tracey O'Connor (T)

Department of Medical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

Ellis Levine (E)

Department of Medical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

Agnieszka K Witkiewicz (AK)

Center for Personalized Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Department of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH